A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot and Dose-Ranging Study of MTPS9579A in Participants With Refractory Chronic Spontaneous Urticaria
Latest Information Update: 12 Oct 2023
At a glance
- Drugs RG-6173 (Primary)
- Indications Chronic urticaria
- Focus Therapeutic Use
- Sponsors Genentech
- 12 Oct 2023 This trial has been Discontinued in Spain according to European Clinical Trials Database record.
- 10 Aug 2022 Status changed from recruiting to withdrawn prior to enrolment.
- 13 Jun 2022 Planned initiation date changed from 30 May 2022 to 31 Jul 2022.